Clinuvel Pharmaceuticals Ltd CLVLF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $9.82
- Day Range
- $9.82–9.82
- 52-Week Range
- $8.57–13.25
- Bid/Ask
- $9.82 / $10.25
- Market Cap
- $492.25 Mil
- Volume/Avg
- 1,530 / 1,759
Key Statistics
- Price/Earnings (Normalized)
- 18.59
- Price/Sales
- 9.63
- Dividend Yield (Trailing)
- 0.33%
- Dividend Yield (Forward)
- 0.21%
- Total Yield
- 0.33%
Company Profile
Clinuvel distributes a single product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient’s quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel’s earnings stem from Europe and the US.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 16
- Website
- https://www.clinuvel.com
Competitors
Valuation
|
Metric
|
CLVLF
|
AVH
|
ABBV
|
|---|---|---|---|
Price/Earnings (Normalized) | 18.59 | — | 15.11 |
Price/Book Value | 4.04 | 4.57 | 28.62 |
Price/Sales | 9.63 | 4.39 | 5.48 |
Price/Cash Flow | 18.51 | — | 14.86 |
Price/Earnings
CLVLF
AVH
ABBV
Financial Strength
|
Metric
|
CLVLF
|
AVH
|
ABBV
|
|---|---|---|---|
Quick Ratio | 6.38 | 7.35 | 0.63 |
Current Ratio | 6.86 | 7.88 | 0.87 |
Interest Coverage | 11.03 | −30.10 | 3.57 |
Quick Ratio
CLVLF
AVH
ABBV
Profitability
|
Metric
|
CLVLF
|
AVH
|
ABBV
|
|---|---|---|---|
Return on Assets (Normalized) | 19.77% | −37.61% | 14.54% |
Return on Equity (Normalized) | 23.18% | −50.88% | 150.11% |
Return on Invested Capital (Normalized) | 22.09% | −44.09% | 28.30% |
Return on Assets
CLVLF
AVH
ABBV
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Fhlpqbcrl | Xvd | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Fqvxcjq | Qxpkmb | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Wgpdxsdr | Dfsbv | $97.8 Bil | |
MRNA
| Moderna Inc | Mzplsbcd | Jlk | $38.8 Bil | |
ARGX
| argenx SE ADR | Sccvlcql | Czqg | $22.0 Bil | |
BNTX
| BioNTech SE ADR | Fhzsbdvg | Dwbr | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Gddrjrjy | Bcbbsvk | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Yhvyczwkd | Txxpkps | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Xqlqfywww | Hlddd | $12.5 Bil | |
INCY
| Incyte Corp | Hktlgslmp | Ydcycvf | $11.5 Bil |